NCT00037687View on ClinicalTrials.gov

Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

PHASE3TerminatedINTERVENTIONAL

Enrollment

2,500

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

December 31, 2004

Conditions

Sepsis

Interventions

DRUG

rPAF-AH

Trial Locations (1)

98021

Mary E. Lonien, M.S., Bothell

Sponsors

Lead Sponsor

ICOS Corporation

All Listed Sponsors

collaborator

Suntory Pharmaceutical

INDUSTRY

lead

ICOS Corporation

INDUSTRY